LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
Loading...
Contact
Check for full-text access
Issue Date
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background: Belzutifan significantly improved progression-free survival (PFS) and objective response rate (ORR) vs everolimus in pts with advanced ccRCC after immune checkpoint and antiangiogenic agents in LITESPARK-005 (NCT04195750).
Description
Citation
Publisher
License
Journal
Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO
Volume
Issue
13-17